Gene test hope for vitamin B-12 metabolism diseases:
This article was originally published in Clinica
Executive Summary
A Canadian team has moved closer to the development early tests for two severe diseases of vitamin B-12 metabolism, after identifying the genes that cause the conditions. The diseases, known as the cblA and cblB forms of methylmalonic aciduria, may produce brain damage, mental retardation and even death if not detected in infancy or early childhood. The genetic discovery could lead to DNA testing for carriers and early prenatal diagnosis, which are important as treatment for the conditions can be started during pregnancy, according to the research, published in Human Molecular Genetics (December 15).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.